Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells

• Published in: Nature communications Vol. 13; no. 1; pp. 5657 - 16
• Main Authors: Wang, Qiwei, Liu, Ying, Wang, Hui, Jiang, Penglei, Qian, Wenchang, You, Min, Han, Yingli, Zeng, Xin, Li, Jinxin, Lu, Huan, Jiang, Lingli, Zhu, Meng, Li, Shilin, Huang, Kang, Tang, Mingmin, Wang, Xinlian, Yan, Liang, Xiong, Zecheng, Shi, Xinghua, Bai, Ge, Liu, Huibiao, Li, Yuliang, Zhao, Yuliang, Chen, Chunying, Qian, Pengxu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.09.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13/31; 14/19; 14/28; 14/5; 38/91; 631/154/155; 631/67/1059/602; 692/4028/67/1059/153; 692/4028/67/1990/283/1897; 82/58; Actin; Acute myeloid leukemia; Age; Apoptosis; Blood cancer; Cell adhesion; Chemotherapy; Cytoskeleton; Deoxyribonucleic acid; DNA; DNA methyltransferase; Drug development; Humanities and Social Sciences; Leukemia; Mannose; multidisciplinary; Mutants; Mutation; Nanomaterials; Nanosheets; Nanotechnology; Phenotypes; Science; Science (multidisciplinary)

DNA methyltransferase 3 A ( DNMT3A ) is the most frequently mutated gene in acute myeloid leukemia (AML). Although chemotherapy agents have improved outcomes for DNMT3A -mutant AML patients, there is still no targeted therapy highlighting the need for further study of how DNMT3A mutations affect AML...